TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11234440

Group type: EXPERIMENTAL
Intervention: Radioactive-fluoridated water (group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inhalation of steam and aerosol using municipal drinking water (group C)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Radioactive-fluoridated waters (group B)
Number of subjects: 27
Study: 8868018

Group type: EXPERIMENTAL
Intervention: Oral prednisolone regimen
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 1519685

Group type: EXPERIMENTAL
Intervention: Topical nonsteroidal anti-inflammatory gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study: 6389647

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.025 micrograms/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 30194849

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) patch
Number of subjects: 4011

Group type: COMPARATOR
Intervention: No GTN patch
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment continued
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Antihypertensive treatment stopped
Number of subjects: 4011
Study: 27725887

Group type: EXPERIMENTAL
Intervention: Endurance Training (treadmill walking for as long as possible)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Precision Training (walking precisely over obstacles and onto targets overground)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endurance Training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Precision Training
Number of subjects: 20
Study: 24682001

Group type: EXPERIMENTAL
Intervention: Humor group (n = 10) watched a humorous video for 20 min.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10) sat calmly for 20 min without distractions.
Number of subjects: 20
Study: 23404432

Group type: EXPERIMENTAL
Intervention: Senior medical student-directed suture skills' training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Experienced faculty surgeon-directed suture skills' training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-directed suture training (control)
Number of subjects: 48
Study: 21080972

Group type: EXPERIMENTAL
Intervention: QUIT-PRIMO intervention (e-referral with paper information-prescription referral)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard patient smoking cessation website
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Augmented patient smoking cessation website (with access to a tobacco treatment specialist online, motivational emails, and an online support group)
Number of subjects: 160
Study: 18648199

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 3 months
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 152
Study: 16965911

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 12834860

Group type: EXPERIMENTAL
Intervention: Brivudin 1 x 125 mg for 7 days
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Acyclovir 5 x 800 mg for 7 days
Number of subjects: 1227
Study: 10230711

Group type: EXPERIMENTAL
Intervention: Tyrosine-rich drink (2 g tyrosine, 5 daily doses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Carbohydrate-rich drink (same calories, 255 kcal)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tyrosine-rich drink
Number of subjects: 21

Group type: COMPARATOR
Intervention: Carbohydrate-rich drink
Number of subjects: 21
Study: 8917032

Group type: EXPERIMENTAL
Intervention: Multiple frequency bioimpedance
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single frequency bioimpedance
Number of subjects: 8
Study: 1871541

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Famotidine (40 mg twice daily)
Number of subjects: 16
Study: 6688261

Group type: EXPERIMENTAL
Intervention: Cadexomer iodine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 34
Study: 3914014

Group type: EXPERIMENTAL
Intervention: Merck‐Sharp and Dohme pneumococcal vaccine (14 serotypes)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Reference group (not vaccinated)
Number of subjects: 1686
Study: 31221935

Group type: EXPERIMENTAL
Intervention: Acupressure applied 2 times per day for 4 weeks (total of 56 sessions) at P6-Lu1-Lu10 acupuncture points.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 0
Study: 29796918

Group type: EXPERIMENTAL
Intervention: Computer-based self-training with CAD as second reader
Number of subjects: 20

Group type: COMPARATOR
Intervention: Computer-based self-training without CAD
Number of subjects: 20
Study: 27433096

Group type: EXPERIMENTAL
Intervention: Topical hemocoagulase spray
Number of subjects: 89

Group type: COMPARATOR
Intervention: Traditional 8% norepinephrine spray
Number of subjects: 89
Study: 23886594

Group type: EXPERIMENTAL
Intervention: Atenolol (ATEN)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Combined therapy (HCTZ and ATEN)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 485
Study: 21975176

Group type: EXPERIMENTAL
Intervention: Allergy vaccination (specific immunotherapy)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alder pollen allergy (natural exposure)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nonallergic subjects
Number of subjects: 27
Study: 18805604

Group type: EXPERIMENTAL
Intervention: Low relative CHD risk
Number of subjects: 375

Group type: COMPARATOR
Intervention: High relative CHD risk
Number of subjects: 375
Study: 18850029

Group type: EXPERIMENTAL
Intervention: Positive environment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Negative environment
Number of subjects: 20
Study: 15725286

Group type: EXPERIMENTAL
Intervention: 0.04% MDBGN applied once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.01% MDBGN applied 4 times daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no MDBGN exposure)
Number of subjects: 31
Study: 12574098

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 16

Group type: COMPARATOR
Intervention: Eprosartan
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10383522

Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 250 mg b.d.)
Number of subjects: 122
Study: 8710739

Group type: EXPERIMENTAL
Intervention: Rac-talinolol 30 mg i.v. and 100 mg p.o. in cholecystectomized patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rac-talinolol 25 mg, 50 mg, 100 mg, and 400 mg p.o. in healthy volunteers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caco-2 cell monolayers permeability study with rac-talinolol concentrations from 0.1 to 2.0 mM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil at 0.5 mM added to Caco-2 cell studies
Number of subjects: 12
Study: 1987387

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg) + Dipyridamole (150 mg)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study: 6352081

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (240,000 IU over 1 hr)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous streptokinase (500,000 IU over 15 min)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous streptokinase (1 million IU over 45 min)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 51
Study: 30835309

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 28856435

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of triamcinolone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Hylan GF20
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Triamcinolone + hylan GF20
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143
Study: 26378739

Group type: EXPERIMENTAL
Intervention: Interactive digital games
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive digital games
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninteractive conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observed player perceived as similar
Number of subjects: 0
Study: 24118079

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30 mg
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 2570
Study: 21272053

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: naproxcinod
Number of subjects: 242

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 242
Study: 18654082

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day) - fully informed group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day) - partially informed group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day) - not informed group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Tadalafil (20 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 16202184

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Haloperidol + Phenytoin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (Haloperidol + Placebo)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 39
Study: 15387395

Group type: EXPERIMENTAL
Intervention: Triplicate Prescription Program (TPP) in New York
Number of subjects: 125837

Group type: COMPARATOR
Intervention: No intervention (New Jersey Medicaid)
Number of subjects: 125837
Study: 11491176

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 0
Study: 9200860

Group type: EXPERIMENTAL
Intervention: Propoxur exposure at 50% relative humidity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propoxur exposure at 70% relative humidity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propoxur exposure at 90% relative humidity
Number of subjects: 0
Study: 7843337

Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of less than 15 cigarettes per day
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 15-24 cigarettes per day
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age < 45)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age 45-54)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age 55-64)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age 65 or over)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (women)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (lowest cholesterol tertile)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (no history of diabetes)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (no hypertension)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (no family history of ischaemic heart disease)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (low body mass index)
Number of subjects: 2022
Study: 3127243

Group type: EXPERIMENTAL
Intervention: Terguride 1 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terguride lower doses
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31664920

Group type: EXPERIMENTAL
Intervention: PCSK9 gene‐centric score (GS)
Number of subjects: 79578

Group type: COMPARATOR
Intervention: PCSK9 inhibitors
Number of subjects: 79578
Study: 28231782

Group type: EXPERIMENTAL
Intervention: D3 daily
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: D3 2-weekly
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: D2 daily
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: D2 2-weekly
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: D2 4-weekly
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: D2/D3
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: D2 and D3
Number of subjects: 279
Study: 25979180

Group type: EXPERIMENTAL
Intervention: School-based sleep education programme (four classroom lessons delivered weekly)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 296
Study: 23448270

Group type: EXPERIMENTAL
Intervention: Kallikrein markers in blood (total, free and intact PSA, kallikrein-related peptidase 2)
Number of subjects: 3654

Group type: COMPARATOR
Intervention: Clinical tests (including DRE and TRUS volume)
Number of subjects: 3654

Group type: EXPERIMENTAL
Intervention: Kallikrein markers with DRE or DRE plus TRUS volume
Number of subjects: 3654

Group type: EXPERIMENTAL
Intervention: Kallikrein markers
Number of subjects: 3654
Study: 22047843

Group type: EXPERIMENTAL
Intervention: Food-cue condition
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Dieting condition
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 166
Study: 20956120

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost in combination with oral bosentan
Number of subjects: 0
Study: 16846448

Group type: EXPERIMENTAL
Intervention: Ding Chuan Tang (DCT) 6.0 g daily for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 12968988

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg orally once daily for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10895398

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study: 9324168

Group type: EXPERIMENTAL
Intervention: UDP-galactosyltransferase activity in gastric mucosa of cirrhotic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: UDP-galactosyltransferase activity in gastric mucosa of patients with chronic hepatitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: UDP-galactosyltransferase activity in gastric mucosa of normal controls
Number of subjects: 0
Study: 8375733

Group type: EXPERIMENTAL
Intervention: Natural interferon-beta (IFN-beta) at two different dose levels (2 x 10(6) IU or 6 x 10(6) IU im 3 times/week for 1 week)
Number of subjects: 43
Study: 3791630

Group type: EXPERIMENTAL
Intervention: Maternal antigen avoidance (dietary advice consisting of almost complete exclusion of milk and dairy products, egg, fish, beef, and peanut throughout pregnancy and lactation)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no dietary restriction)
Number of subjects: 121
Study: 29614063

Group type: EXPERIMENTAL
Intervention: FOLFOX4 (FFO group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (FFIO group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery (Control group)
Number of subjects: 0
Study: 26922655

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication discontinuation
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Successful discontinuation (defined as no relapse within the observation period)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Successful discontinuation (defined as no relapse and symptomatic remission at 12-month follow-up)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Discontinuation predictors
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Quality of life and compliance
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Successful discontinuation predictors (definition a)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Successful discontinuation predictors (definition b)
Number of subjects: 325
Study: 23718182

Group type: EXPERIMENTAL
Intervention: Saucer-shaped defects
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Wedge-shaped defects
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Flat defects
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Undercut defects
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Slit-like defects
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intra-observer reliability
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Association of PIBD type
Number of subjects: 83
Study: 22813676

Group type: EXPERIMENTAL
Intervention: WPS (Workplace Solutions) intervention group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Total best-practice implementation
Number of subjects: 48
Study: 20506282

Group type: EXPERIMENTAL
Intervention: EPC stent
Number of subjects: 100

Group type: COMPARATOR
Intervention: CoCr stent
Number of subjects: 100
Study: 18942901

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg tid; n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study: 16158479

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (n=74)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (n=65)
Number of subjects: 139
Study: 12934778

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (Oxytrol, 3.9 mg/d)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Extended-release oral oxybutynin (Ditropan XL, 10 mg)
Number of subjects: 13
Study: 10393376

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (trimethoprim, 320 mg/day; sulfamethoxazole, 1,600 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Other antibiotics (control group)
Number of subjects: 97
Study: 8894571

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) 1 g/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8236992

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 30
Study: 3318145

Group type: EXPERIMENTAL
Intervention: 1.5 mg PG E2 endocervically
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 3 mg PG E2 intravaginally
Number of subjects: 158

Group type: COMPARATOR
Intervention: Spontaneous onset of labour (control group)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pretherapeutic oxytocin sensitivity test
Number of subjects: 158
Study: 29798906

Group type: EXPERIMENTAL
Intervention: AZD1775
Number of subjects: 20
Study: 25967528

Group type: EXPERIMENTAL
Intervention: AGV with MMC (group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AGV with AMT (group C)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional AGV implantation (group A)
Number of subjects: 75
Study: 26455718

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Artificial endometrial cycle treatment (AEC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Comforting false Han's placebo (FHP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 240
Study: 24385637

Group type: EXPERIMENTAL
Intervention: Nondrivers
Number of subjects: 2793

Group type: COMPARATOR
Intervention: Drivers
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Large-city residents
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Small-city residents
Number of subjects: 2793
Study: 20807919

Group type: EXPERIMENTAL
Intervention: Left arm in an above-the-elbow thumb spica splint
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Left arm in a below-the-elbow splint
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All splints
Number of subjects: 36
Study: 17977859

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.165% with sufentanil 1 microg ml(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Levobupivacaine 0.125% with sufentanil 1 microg ml(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.165%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Levobupivacaine 0.125%
Number of subjects: 100
Study: 16365120

Group type: EXPERIMENTAL
Intervention: Clamping the drains after intra‐articular injection of saline with 1:500 000 adrenaline
Number of subjects: 212

Group type: COMPARATOR
Intervention: Post-operative blood salvage
Number of subjects: 212
Study: 14710587

Group type: EXPERIMENTAL
Intervention: Brief exposure of gametes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF)
Number of subjects: 0
Study: 10847459

Group type: EXPERIMENTAL
Intervention: Eniluracil-5-FU
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Eniluracil-5-FU-LV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Eniluracil-5-FU (refractory stratum)
Number of subjects: 75
Study: 7674690

Group type: EXPERIMENTAL
Intervention: Judicious prescription of therapies in stepwise fashion
Number of subjects: 0
Study: 2469338

Group type: EXPERIMENTAL
Intervention: Hypertonic saline‐dextran solution
Number of subjects: 48

Group type: COMPARATOR
Intervention: Crystalloid plasmalyte A
Number of subjects: 48
Study: 407377

Group type: EXPERIMENTAL
Intervention: Lactose diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-lactose diet
Number of subjects: 16